Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

68.53
-1.0700-1.54%
Post-market: 68.530.00000.00%19:33 EDT
Volume:1.52M
Turnover:103.83M
Market Cap:13.29B
PE:-18.13
High:69.28
Open:68.87
Low:67.57
Close:69.60
52wk High:84.94
52wk Low:28.33
Shares:193.86M
Float Shares:151.20M
Volume Ratio:0.92
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7800
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-33.83%
PB:-6.37
PE(LYR):-18.11

Loading ...

BridgeBio to present long-term ATTRibute-CM open-label extension data on acoramidis at ACC 2026

Reuters
·
Mar 23

BridgeBio Pharma reports inducement RSU grants covering 70,916 shares for 29 new employees

Reuters
·
Mar 21

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 21

BridgeBio Pharma Inc : Mizuho Raises Target Price to $106 From $91

THOMSON REUTERS
·
Mar 19

U.S. RESEARCH ROUNDUP-Carnival, Five Below, McKesson

Reuters
·
Mar 19

BridgeBio Oncology Therapeutics to present research at AACR Annual Meeting 2026

Reuters
·
Mar 19

Bank of America Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Mar 17

BridgeBio Pharma CEO Neil Kumar disposes of USD 4.58 million in common shares

Reuters
·
Mar 17

A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility

Simply Wall St.
·
Mar 12

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Mar 12

BRIEF-Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026

Reuters
·
Mar 12

BridgeBio presents Phase 3 FORTIFY interim analysis results

TIPRANKS
·
Mar 12

BridgeBio Pharma Inc - to Submit Nda for Bbp-418 to FDA in H1 2026

THOMSON REUTERS
·
Mar 12

BridgeBio Pharma Inc - Bbp-418 Well Tolerated With Safety Profile Comparable to Placebo

THOMSON REUTERS
·
Mar 12

Bbp-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 Fortify Interim Analysis in Lgmd2i/R9

THOMSON REUTERS
·
Mar 12

BridgeBio reports Phase 3 FORTIFY interim results showing BBP-418 improved 100-meter timed test by 31 seconds at 12 months

Reuters
·
Mar 12

BridgeBio Pharma Initiated at Outperform by William Blair

Dow Jones
·
Mar 10

BridgeBio Pharma (BBIO) Receives a Buy from William Blair

TIPRANKS
·
Mar 10

U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx

Reuters
·
Mar 10

BridgeBio Pharma Inc : JP Morgan Adds Stock to Its US Analyst Focus List

THOMSON REUTERS
·
Mar 10